News and Analysis

iECURE grabs $50m Series A

iECURE, a mutation-agnostic in vivo gene editing company, has secured $50 million in Series A financing.

-

iECURE, a mutation-agnostic in vivo gene editing company, has secured $50 million in Series A financing. Versant Ventures and OrbiMed Advisors led the round.

Source: Press Release